ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2231

Ixekizumab Significantly Improves Nail Disease and Adjacent Joint Tenderness and Swelling in Psoriatic Arthritis

Dennis McGonagle1, Arthur Kavanaugh2, Iain McInnes3, Lars Erik4, Joseph Merola5, Bruce Strober6, Rebecca Bolce7, Jeffrey Lisse7, Jennifer Pustizzi7, Christophe Sapin7 and Christopher T Ritchlin8, 1Leeds Teaching Hospitals NHS Trust, Academic Unit for the Musculoskeletal Diseases, Leeds, United Kingdom, 2Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, 3University of Glasgow, Glasgow, United Kingdom, 4Bispebjerg-Frederiksberg Hospital, Vedbæk, Denmark, 5Harvard Medical School, Brigham and Women's Hospital, Newton, MA, 6Yale University, New Haven, CT, 7Eli Lilly and Company, Indianapolis, IN, 8University of Rochester Medical School, Allergy, Immunology & Rheumatology Division, Canandaigua, NY

Meeting: ACR Convergence 2023

Keywords: Biologicals, Disease-Modifying Antirheumatic Drugs (Dmards), hand, Psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2227–2256) Spondyloarthritis Including Psoriatic Arthritis – Treatment: SpA Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Nail psoriasis (PsO) is a strong predictor for the development of psoriatic arthritis (PsA) and has been reported in 63–83% of patients with PsA1. Psoriatic nails are linked to arthritis in the adjacent distal interphalangeal joint (DIP) of fingers or interphalangeal joint of thumbs2, and both can lead to severe functional impairment. In the SPIRIT-H2H study of adults with PsA, 354 of 566 participants had nail PsO and adjacent joint disease in at least one digit at baseline3-4. At the group level, SPIRIT-H2H patients treated with ixekizumab (IXE) achieved significantly greater improvements in nail PsO compared to those treated with adalimumab (ADA)5. This analysis aimed to assess the treatment effects of IXE and ADA at the individual digit level among patients with PsA, nail PsO, and adjacent joint disease.

Methods: This post hoc analysis included 354 patients from SPIRIT-H2H (NCT03151551) treated with either IXE (N=186) or ADA (N=168) who had nail PsO (Nail Psoriasis Severity Index (NAPSI) total score >0) and adjacent joint disease (tenderness and/or swelling) in at least one digit at baseline. Treatment effects were assessed for each individual finger unit displaying nail PsO and adjacent joint disease; here, finger unit defines the nail and adjacent joint of an individual digit; adjacent joint refers to the DIP of fingers or the interphalangeal joint of thumbs. Nail PsO was measured using NAPSI in the fingers only. Joint involvement was measured by tender/swollen joint count scores (TJC68/SJC66). Patients were evaluated for both nail and joint involvement at baseline and Weeks 12, 16, 24, 32, 40, and 52. Proportions of finger units with resolution of nail PsO, and proportions of finger units with resolution of adjacent joint disease were analyzed using Chi-square tests. Non-responder imputation was used to handle missing data.

Results: There were 1309 (IXE=639, ADA=670) finger units affected by nail and adjacent joint disease at baseline (Table 1). Resolution of psoriatic nail disease (Figure 1A) and resolution of adjacent tenderness and/or swelling (Figure 1B) of the finger unit was significantly higher with IXE vs ADA at all post-baseline assessments over 52 weeks. Joint tenderness was resolved in a significantly larger proportion of IXE-treated finger units vs ADA at all post-baseline assessments over 52 weeks (Figure 2A). Joint swelling was resolved in a larger proportion of IXE-treated finger units vs ADA, and these differences reached statistical significance at all visits except Week 16 and Week 40 (Figure 2B). The tenderness and/or swelling of the finger unit resolved more rapidly than the adjacent nail disease (Figure 1).

Conclusion: IXE treatment showed a significant advantage over ADA in resolving nail PsO, joint tenderness, and joint swelling among the finger units with nail and adjacent joint disease of patients with PsA.

References
1. Elkayam O et al. Clin Rheumatol. 2000; 19(4): 301-305.
2. Lai TL et al. Clin Rheumatol. 2016; 35(8): 2031-2037
3. McGonagle D et al. British Society for Rheumatology. 2023; P169
4. McGonagle D et al. European Alliance of Associations for Rheumatology. 2023; POS1526
5. Smolen JS et al. Rheumatol Ther. 2020;7(4):1021-35

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: D. McGonagle: AbbVie, 2, 5, 6, Celgene, 2, 5, 6, Eli Lilly, 5, 6, 12, Paid Instructor, Janssen, 2, 5, 6, Merck, 2, 5, 6, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, UCB, 2, 5, 6; A. Kavanaugh: Amgen, 2, BMS, 2, Eli Lilly, 2, Novartis, 2, Pfizer, 2, UCB, 2; I. McInnes: AbbVie, 2, Amgen, 2, AstraZeneca, 2, Bristol Myers Squibb, 2, 5, Cabaletta, 2, 11, Causeway Therapeutics, 2, 11, Celgene, 2, 5, Compugen, 2, 11, Dextera, 11, Eli Lilly, 2, EveloBio, 1, 2, 4, 11, Gilead, 2, Janssen, 2, 5, Moonlake, 2, NHS GGC, 4, Novartis, 2, 5, Pfizer, 2, Sanofi, 2, UCB, 2, 5, Versus Arthritis, 12, Trustee Status; L. Erik: AbbVie, 2, 5, 6, Amgen, 2, 6, Biogen, 2, 6, Bristol-Myers Squibb, 2, 6, Eli Lilly, 2, 5, 6, Gilead, 2, 6, Janssen, 2, 6, MSD, 2, 6, Novartis, 2, 5, 6, Pfizer, 2, 6, UCB, 2, 5, 6; J. Merola: Abbvie, 2, 12, Investigator, Amgen, 2, 12, Investigator, Biogen, 2, 12, Investigator, Bristol-Myers Squibb, 2, 12, Investigator, Dermavant, 2, 12, Investigator, Eli Lilly, 2, 6, 12, Investigator, Janssen, 2, 12, Investigator, Leo Pharma, 2, 12, Investigator, Novartis, 2, 12, Investigator, Pfizer, 2, 12, Investigator, Regeneron, 2, 12, Investigator, Sanofi, 2, 12, Investigator, Sun Pharma, 2, 12, Investigator, UCB Pharma, 2, 12, Investigator; B. Strober: AbbVie, 6, 6, Alamar, 6, Almirall, 6, Alumis, 6, Amgen, 6, Arcutis, 6, 6, Arena, 6, Aristea, 6, Asana, 6, Boehringer Ingelheim, 6, Bristol Myers Squibb, 12, Consultancy honoraria, Connect Biopharma, 6, 11, CorEvitas, 6, CorEvitas Psoriasis Registry, 12, Scientific Co-Director (consulting fee), 12, Investigator, Dermavant, 6, 6, Dermira, 12, Investigator, Eli Lilly, 6, 6, Evelo Biosciences, 6, Immunic Therapeutics, 6, Incyte, 6, Janssen, 6, 6, Journal of Psoriasis and Psoriatic Arthritis, 6, Leo, 6, Maruho, 6, Meiji Seika Pharma, 6, Mindera Health, 6, 11, Novartis, 6, Pfizer, 6, Protagonist, 6, Regeneron, 6, 6, Sanofi-Genzyme, 6, 6, Sun Pharma, 6, UCB Pharma, 6, Union Therapeutics, 6, Ventyxbio, 6, vTv Therapeutics, 6; R. Bolce: Eli Lilly and Company, 3, 11; J. Lisse: Eli Lilly and Company, 3, 11; J. Pustizzi: Eli Lilly, 3, 11; C. Sapin: Eli Lilly, 3, 11; C. Ritchlin: AbbVie, 2, 5, 6, Amgen, 2, BMS, 2, Eli Lilly, 2, Gilead, 2, Janssen, 2, Novartis, 2, Pfizer, 2, 5, 6, UCB, 2, 6.

To cite this abstract in AMA style:

McGonagle D, Kavanaugh A, McInnes I, Erik L, Merola J, Strober B, Bolce R, Lisse J, Pustizzi J, Sapin C, Ritchlin C. Ixekizumab Significantly Improves Nail Disease and Adjacent Joint Tenderness and Swelling in Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/ixekizumab-significantly-improves-nail-disease-and-adjacent-joint-tenderness-and-swelling-in-psoriatic-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ixekizumab-significantly-improves-nail-disease-and-adjacent-joint-tenderness-and-swelling-in-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology